Status:
TERMINATED
Ph I Ipilimumab Vemurafenib Combo in Patients With v-Raf Murine Sarcoma Viral Oncogene Homolog B1 (BRAF)
Lead Sponsor:
Bristol-Myers Squibb
Collaborating Sponsors:
Roche-Genentech
Conditions:
Melanoma
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
Treatment of subjects who have metastatic melanoma that expresses an activated mutant form of the BRAF oncogene (V600E) with a combination of the specific BRAF inhibitor, Vemurafenib, and the Cytotoxi...
Eligibility Criteria
Inclusion
- For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com.
- Metastatic melanoma with activating V600 BRAF mutation
- Measurable Tumor
- Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0-1
Exclusion
- Autoimmune disease
- Active Brain Metastasis (must be stable after radiation for at least one month)
- Prior therapy with immune stimulating agents
Key Trial Info
Start Date :
November 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2013
Estimated Enrollment :
18 Patients enrolled
Trial Details
Trial ID
NCT01400451
Start Date
November 1 2011
End Date
December 1 2013
Last Update
January 1 2015
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
University Of California Los Angeles
Los Angeles, California, United States, 90095
2
Dana Farber Cancer Institute
Boston, Massachusetts, United States, 02215
3
Dana Farber Cancer Inst
Boston, Massachusetts, United States, 02215
4
Memorial Sloan-Kettering Cancer Center
New York, New York, United States, 10065